These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 29180095)

  • 1. Drug survival of secukinumab in real-world plaque psoriasis patients: A 52-week, multicenter, retrospective study.
    Georgakopoulos JR; Ighani A; Phung M; Yeung J
    J Am Acad Dermatol; 2018 May; 78(5):1019-1020. PubMed ID: 29180095
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies.
    Georgakopoulos JR; Phung M; Ighani A; Yeung J
    J Am Acad Dermatol; 2018 Jul; 79(1):155-157. PubMed ID: 29307635
    [No Abstract]   [Full Text] [Related]  

  • 3. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
    Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
    J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of severe psoriasis relapse with secukinumab (interleukin 17 A inhibitor) after abrupt brodalumab (interleukin 17 receptor inhibitor) discontinuation: A retrospective study evaluating long-term efficacy and safety.
    Khemis A; Kelati A; Montaudié H; Lacour JP; Passeron T
    J Am Acad Dermatol; 2018 Oct; 79(4):758-760. PubMed ID: 29596876
    [No Abstract]   [Full Text] [Related]  

  • 5. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study.
    Schwensen JF; Clemmensen A; Sand C; Gniadecki R; Skov L; Zachariae C; Iversen L; Rasmussen M; Thomsen SF
    Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28906051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug survival of apremilast in patients treated for psoriasis in a real-world setting.
    Lee EB; Amin M; Wu JJ
    J Am Acad Dermatol; 2018 Oct; 79(4):760-761. PubMed ID: 29588246
    [No Abstract]   [Full Text] [Related]  

  • 7. Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification - rationale and design of the randomized, multicenter STEPIn study.
    Iversen L; Eidsmo L; Austad J; de Rie M; Osmancevic A; Skov L; Talme T; Bachmann I; van de Kerkhof P; Stahle M; Banerjee R; Oliver J; Fasth AER; Frueh J
    J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):1930-1939. PubMed ID: 29633373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug survival, discontinuation rates, and safety profile of secukinumab in real-world patients: a 152-week, multicenter, retrospective study.
    Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Galán-Gutierrez M; Armario-HIta JC; Martinez-Pilar L
    Int J Dermatol; 2020 May; 59(5):633-639. PubMed ID: 32173862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study.
    Georgakopoulos JR; Ighani A; Zhou LL; Yeung J
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e32-e34. PubMed ID: 28695989
    [No Abstract]   [Full Text] [Related]  

  • 10. Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: A 104-week clinical study.
    Rompoti N; Katsimbri P; Kokkalis G; Boumpas D; Ikonomidis I; Theodoropoulos K; Rigopoulos D; Papadavid E
    Dermatol Ther; 2019 Sep; 32(5):e13006. PubMed ID: 31228319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment optimization with secukinumab 150 mg for moderate-to-severe psoriasis in clinical practice: a single-center open-label 52-week study.
    Muñoz-Santos C; Sola-Ortigosa J; Guilabert A
    Int J Dermatol; 2018 May; 57(5):615-617. PubMed ID: 29453809
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.
    Imafuku S; Honma M; Okubo Y; Komine M; Ohtsuki M; Morita A; Seko N; Kawashima N; Ito S; Shima T; Nakagawa H
    J Dermatol; 2016 Sep; 43(9):1011-7. PubMed ID: 26919410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial.
    Gottlieb AB; Blauvelt A; Prinz JC; Papanastasiou P; Pathan R; Nyirady J; Fox T; Papavassilis C
    J Drugs Dermatol; 2016 Oct; 15(10):1226-1234. PubMed ID: 27741340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance of therapeutic response after 1 year of apremilast combination therapy compared with monotherapy for the treatment of plaque psoriasis: A multicenter, retrospective study.
    Ighani A; Georgakopoulos JR; Shear NH; Walsh S; Yeung J
    J Am Acad Dermatol; 2018 Nov; 79(5):953-956. PubMed ID: 29730366
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: A single-center experience.
    Momose M; Asahina A; Umezawa Y; Nakagawa H
    J Dermatol; 2018 Mar; 45(3):318-321. PubMed ID: 29194723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis.
    Menter A; Thaçi D; Papp KA; Wu JJ; Bereswill M; Teixeira HD; Rubant S; Williams DA
    J Am Acad Dermatol; 2015 Sep; 73(3):410-9.e6. PubMed ID: 26190240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab.
    Rongioletti F; Borenstein M; Kirsner R; Kerdel F
    J Dermatolog Treat; 2003 Dec; 14(4):222-5. PubMed ID: 14660268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study.
    Körber A; Thaçi D; von Kiedrowski R; Bachhuber T; Melzer N; Kasparek T; Kraehn-Senftleben G; Amon U; Augustin M
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):411-419. PubMed ID: 28960469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).
    Blauvelt A; Prinz JC; Gottlieb AB; Kingo K; Sofen H; Ruer-Mulard M; Singh V; Pathan R; Papavassilis C; Cooper S;
    Br J Dermatol; 2015 Feb; 172(2):484-93. PubMed ID: 25132411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study.
    Torres T; Balato A; Conrad C; Conti A; Dapavo P; Ferreira P; Gaiani F; Leite L; Malagoli P; Mendes-Bastos P; Megna M; Messina F; Nidegger A; Odorici G; Piaserico S; Prignano F; Ribero S; Ricceri F; Tonini A; Valério J; Chiricozzi A
    J Am Acad Dermatol; 2019 Jul; 81(1):273-275. PubMed ID: 30790602
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.